Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation

по Pal, Akos, Asad, Yasmin, Ruddle, Ruth, Henley, Alan T., Swales, Karen, Decordova, Shaun, Eccles, Suzanne A ., Collins, Ian, Garrett, Michelle D., De Bono, Johann, Banerji, Udai, Raynaud, Florence I.
Опубликовано в: Metabolomics (2020)

First-in-Human study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics and Pharmacodynamics, in Patients with Metastatic Cancer

по Blagden, Sarah, Olmin, Aurelius, Josephs, Debra, Stavraka, Chara, Zivi, Andrea, Pinato, David J., Anthoney, Alan, Decordova, Shaun, Swales, Karen, Riisnaes, Ruth, Pope, Lorna, Noguchi, Kohei, Shiokawa, Rie, Inatani, Michiyasu, Prince, Jenny, Jones, Keith, Twelves, Chris, Spicer, James, Banerji, Udai
Опубликовано в: Clin Cancer Res (2014)

First-in-human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors

по McLeod, Robert, Kumar, Rajiv, Papadatos-Pastos, Dionysis, Mateo, Joaquin, Brown, Jessica S, Garces, Alvaro H Ingles, Ruddle, Ruth, Decordova, Shaun, Jueliger, Simone, Ferraldeschi, Roberta, Maiques, Oscar, Sanz-Moreno, Victoria, Jones, Paul, Traub, Stephanie, Halbert, Gavin, Mellor, Sarah, Swales, Karen E, Raynaud, Florence I, Garrett, Michelle D, Banerji, Udai
Опубликовано в: Clin Cancer Res (2020)

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers

по Yap, Timothy A., Yan, Li, Patnaik, Amita, Tunariu, Nina, Biondo, Andrea, Fearen, Ivy, Papadopoulos, Kyriakos P., Olmos, David, Baird, Richard, Delgado, Liliana, Tetteh, Ernestina, Beckman, Robert A., Lupinacci, Lisa, Riisnaes, Ruth, Decordova, Shaun, Heaton, Simon P., Swales, Karen, deSouza, Nandita M, Leach, Martin O., Garrett, Michelle D., Sullivan, Daniel M., de Bono, Johann S., Tolcher, Anthony W.
Опубликовано в: Clin Cancer Res (2014)

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

по Yap, Timothy A., Kristeleit, Rebecca, Michalarea, Vasiliki, Pettitt, Stephen J., Lim, Joline S.J., Carreira, Suzanne, Roda, Desamparados, Miller, Rowan, Riisnaes, Ruth, Miranda, Susana, Figueiredo, Ines, Rodrigues, Daniel Nava, Ward, Sarah, Matthews, Ruth, Parmar, Mona, Turner, Alison, Tunariu, Nina, Chopra, Neha, Gevensleben, Heidrun, Turner, Nicholas C., Ruddle, Ruth, Raynaud, Florence I., Decordova, Shaun, Swales, Karen E., Finneran, Laura, Hall, Emma, Rugman, Paul, Lindemann, Justin P.O., Foxley, Andrew, Lord, Christopher J., Banerji, Udai, Plummer, Ruth, Basu, Bristi, Lopez, Juanita S., Drew, Yvette, de Bono, Johann S.
Опубликовано в: Cancer Discov (2020)